RxDoctor Payments Data

Belinda Hara, MD

Psychiatry · Los Angeles, CANPI 1508080250

Payments from drug & device makers

$1,075in general payments, 2019–2025

Across 55 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$285
  • Neurocrine Biosciences, Inc.$171
  • Indivior Inc.$132
  • Johnson & Johnson$131
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$91
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$81
  • plus $183 from 4 others

What the payments were for

  • Food & beverage$1,075100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,075 in reported general payments places this provider in the 75th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$20,976
Medicare patients
41
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole37$106,692
Invega SustennaPaliperidone Palmitate32$96,445
Aripiprazole160$4,616
Olanzapine74$2,275
Quetiapine Fumarate51$2,035
Divalproex Sodium ErDivalproex Sodium30$1,572
Lurasidone Hcl18$798
Clonazepam37$764
Trazodone Hcl157$753
Risperidone88$581
Sertraline Hcl98$513
Citalopram HbrCitalopram Hydrobromide41$501
Hydroxyzine Hcl43$488
Mirtazapine50$479
Divalproex Sodium36$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$65$106,69237 claims
Johnson & JohnsonInvega Sustenna$131$96,44532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →